World J Mens Health.  2017 Dec;35(3):134-145. 10.5534/wjmh.17033.

Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option

• Gabrielson AT
• Alzweri LM
• Hellstrom

• KMID: 2398562
• DOI: http://doi.org/10.5534/wjmh.17033

Abstract

Peyronie's disease (PD) is an inflammatory disorder characterized by an abnormal collagen deposition in the tunica albuginea of the penis, leading to fibrous and non-compliant plaques that can impede normal erection. Although pharmacological treatments are available, only intralesional injection therapy and surgical reconstruction have demonstrated tangible clinical efficacy in the management of this condition. Intralesional injection of collagenase clostridium histolyticum (CCH) has come to the forefront of minimally invasive treatment of PD. In this review, the authors provide an update on the safety, efficacy, and indications for CCH. The efficacy of CCH will be assessed on the basis of improvement in the severity of penile fibrosis, curvature, and pain. Numerous well-designed clinical trials and post-approval studies involving more than 1,500 patients have consistently demonstrated the efficacy and tolerability of CCH in the treatment of PD. CCH significantly decreases penile curvature and plaque consistency, as well as improves quality of life. Post-approval studies continue to demonstrate the efficacy of CCH despite broader inclusion criteria for treatment, such as the case with acute phase disease and atypical plaque deformities (i.e., ventral plaques, hourglass narrowing). CCH continues to be the gold standard for non-surgical management of stable phase PD, in the absence of strong evidence supporting oral therapy agents and ongoing evaluation of extracorporeal shockwave therapy. However, recent studies are beginning to provide precedent for the use of CCH in the management of acute phase and atypical PD.

Keyword

Injections, intralesional; Microbial collagenase; Penile Induration; Therapeutics; Urologic diseases

MeSH Terms

Collagen
Collagenases*
Congenital Abnormalities
Fibrosis
Humans
Injections, Intralesional
Male
Microbial Collagenase*
Penile Induration*
Penis
Quality of Life
Treatment Outcome
Urologic Diseases
Collagen
Collagenases
Microbial Collagenase

Figure

• 

  Fig. 1 Flowchart demonstrating differences between the Investigation of Maximal Peyronie's Reduction Efficacy and Safety Studies (IMPRESS) trial protocol and shortened modified protocol. CCH: collagenase clostridium histolyticum.

Reference

1. Endo Pharmaceuticals Inc. Xiaflex® (Collagenase Clostridium histolyticum) [prescribing information]. Malvern (PA): Endo Pharmaceuticals Inc.;2016. p. 1–42.

2. Mandl I, Maclennan JD, Howes EL, DeBellis RH, Sohler A. Isolation and characterization of proteinase and collagenase from Cl. histolyticum. J Clin Invest. 1953; 32:1323–1329.

3. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol. 1985; 134:280–283.

4. French MF, Mookhtiar KA, Van Wart HE. Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry. 1987; 26:681–687.

5. Kono T. Purification and partial characterization of collagenolytic enzymes from Clostridium histolyticum. Biochemistry. 1968; 7:1106–1114.

6. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res. 1982; 10:135–140.

7. Levine LA, Schmid TM, Emeigh Hart SG, Tittelbach T, McLane MP, Tursi JP. PD22-03. Collagenase clostridium histolyticum degrades type I and III Collagen while sparing Type IV collagen in vitro in Peyronie's plaque explants. J Urol. 2014; 191:e672–e673.

8. Auxilium Pharmaceuticals. Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men with Peyronie's Disease. Bethesda (MD): National Library of Medicine;2011.

9. Desai SS, Hentz VR. Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opin Biol Ther. 2010; 10:1395–1404.

10. Rydevik B, Brown MD, Ehira T, Nordborg C. Effects of collagenase on nerve tissue. An experimental study on acute and long-term effects in rabbits. Spine (Phila Pa 1976). 1985; 10:562–566.

11. Rydevik B, Ehira T, Linder L, Olmarker K, Romanus M, Brånemark PI. Microvascular response to locally injected collagenase. An experimental investigation in hamsters and rabbits. Scand J Plast Reconstr Surg Hand Surg. 1989; 23:17–21.

12. Mookhtiar KA, Van Wart HE. Clostridium histolyticum collagenases: a new look at some old enzymes. Matrix Suppl. 1992; 1:116–126.

13. Garvin PJ Jr. Toxicity of collagenase: the relation to enzyme therapy of disk herniation. Clin Orthop Relat Res. 1974; (101):286–291.

14. Jung CM, Matsushita O, Katayama S, Minami J, Sakurai J, Okabe A. Identification of metal ligands in the Clostridium histolyticum ColH collagenase. J Bacteriol. 1999; 181:2816–2822.

15. Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie's disease in Japan: a study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med. 2012; 9:2716–2723.

16. El-Sakka AI, Tayeb KA. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol. 2005; 174:1026–1030.

17. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007; 19:213–217.

18. El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol. 2006; 49:564–569.

19. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991; 146:1007–1009.

20. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001; 88:727–730.

21. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004; 171:2350–2353.

22. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States. Adv Urol. 2011; DOI: 10.1155/2011/282503. [Epub].

23. Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie's disease in the United States: a population-based study. PLoS One. 2016; 11:e0150157.

24. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie's disease: AUA guideline. J Urol. 2015; 194:745–753.

25. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997; 158:1391–1394.

26. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol. 1998; 81:445–452.

27. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, et al. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000; 163:1992–1998.

28. Francisco G, Ling DY, Eric C, Michael B, Gerald B. MP-06.02. A Novel rat model for Peyronie's disease that demonstrates durability and functional detriments. CUA J. 2012; 6:S51.

29. Berookhim BM, Choi J, Alex B, Mulhall JP. Deformity stabilization and improvement in men with untreated Peyronie's disease. BJU Int. 2014; 113:133–136.

30. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006; 175:2115–2118.

31. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol. 1998; 51:511–515.

32. Rhoden EL, Riedner CE, Fuchs SC, Ribeiro EP, Halmenschlager G. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie's disease. J Sex Med. 2010; 7:1529–1537.

33. Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie's disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010; 7:1254–1261.

34. Jordan GH, McCammon KA. Peyronie's disease. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders;2007. p. 792–809.

35. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of peyronie's disease. Br J Urol. 1982; 54:748–750.

36. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie's disease. J Sex Med. 2016; 13:905–923.

37. Jack GS, Gonzalez-Cadavid N, Rajfer J. Conservative management options for Peyronie's disease. Curr Urol Rep. 2005; 6:454–460.

38. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003; 169:1775–1778.

39. Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease: a placebo-controlled pilot study. J Sex Med. 2007; 4:477–484.

40. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol. 2007; 177:972–975.

41. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004; 171:740–745.

42. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009; 56:363–369.

43. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010; 106:1352–1356.

44. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013; 10:2815–2821.

45. Müller A, Akin-Olugbade Y, Deveci S, Donohue JF, Tal R, Kobylarz KA, et al. The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue. Eur Urol. 2008; 53:635–642.

46. Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol. 2007; 51:640–647.

47. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006; 176:394–398.

48. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006; 67:1038–1042.

49. Wolf SE, Nicolai M, Dagenais G. Growth hormone treatment in catabolic states other than burns. Growth Horm IGF Res. 1998; 8:Suppl B. 117–119.

50. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998; 51:620–626.

51. Wolff B, Peyronnet B, Cattarino S, Mozer P, Renard-Penna R, Phé V, et al. Intralesional injections for early peyronie disease: standardized assessment and analysis of predictive factors for treatment response. Urology. 2015; 86:57–61.

52. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebocontrolled study. Int Urol Nephrol. 2009; 41:467–471.

53. Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ. Role of collagenase clostridium histolyticum in Peyronie's disease. Biologics. 2015; 9:107–116.

54. Dean RC, Lue TF. Peyronie's disease: advancements in recent surgical techniques. Curr Opin Urol. 2004; 14:339–343.

55. Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie's disease. J Urol. 1997; 158:2149–2152.

56. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. Eur Urol. 2012; 62:543–552.

57. Yang KK, Bennett N. Peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016; 94:143–147.

58. Anaissie J, Yafi FA, DeLay KJ, Traore EJ, Sikka SC, Hellstrom WJ. Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie's disease. Urology. 2017; 100:125–130.

59. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol. 1993; 149:56–58.

60. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008; 5:180–187.

61. Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012; 187:2268–2274.

62. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013; 190:199–207.

63. Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015; 12:248–258.

64. Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie's disease. J Urol. 2016; 195:1051–1056.

65. Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015; 116:650–656.

66. Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int. 2017; DOI: 10.1111/bju.13932. [Epub].

67. Yafi FA, Hatzichristodoulou G, Knoedler CJ, Trost LW, Sikka SC, Hellstrom WJ. Comparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie's disease. J Sex Med. 2015; 12:2492–2498.

68. Yafi FA, Hatzichristodoulou G, DeLay KJ, Hellstrom WJ. Review of management options for patients with atypical Peyronie's disease. Sex Med Rev. 2017; 5:211–221.

69. Milam D. 116. Positive results with collagenase clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie's disease. J Sex Med. 2016; 13:S55.

70. Stewart CA, Yafi FA, Knoedler M, Mandava SH, McCaslin IR, Sangkum P, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie's disease independent of plaque location. J Urol. 2015; 194:1704–1707.